Abstract
Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as anticancer agents. Their biological characteristics as well as structure-activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.
Keywords:
Anticancer; Antiproliferative; Imidazo[2,1-b]thiazole; Imidazothiazole; Kinase inhibitor; Tubulin.
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Drug Screening Assays, Antitumor
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Imidazoles / chemistry*
-
Models, Molecular
-
Protein Binding
-
Protein Kinase Inhibitors / chemistry*
-
Protein Kinase Inhibitors / pharmacology
-
Ribosomal Protein S6 Kinases, 90-kDa / antagonists & inhibitors
-
Signal Transduction
-
Structure-Activity Relationship
-
Thiazoles / chemistry*
-
Thiazoles / pharmacology
-
Tubulin / metabolism
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Protein Kinase Inhibitors
-
Thiazoles
-
Tubulin
-
ErbB Receptors
-
Ribosomal Protein S6 Kinases, 90-kDa
-
ribosomal protein S6 kinase, 90kDa, polypeptide 3